NKTR

$75.06

Pre-MarketAs of Mar 17, 8:00 PM UTC

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

The Fly
Mar 17, 2026

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Wall Street Analysts See a 77.28% Upside in Nektar (NKTR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Company News for Mar 16, 2026

Companies In The News Are: ADBE, META, NKTR, ORKA.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 13, 2026

Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus

NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Moby
Mar 13, 2026

Nektar Therapeutics Q4 2025 Earnings Call Summary

Moby summary of Nektar Therapeutics's Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.